

# PRIMARY CANCER SITE TABLE

NCH 2018 Analytic Cases\*



Body System and Site	Total	%	Male	Female
<b>ORAL CAVITY &amp; PHARYNX</b>	<b>21</b>	<b>1.5%</b>	<b>15</b>	<b>6</b>
Tongue	10	0.7%	6	4
Salivary Glands	2	0.1%	0	2
Floor of Mouth	2	0.1%	2	0
Gum & Other Mouth	1	0.1%	1	0
Tonsil	3	0.2%	3	0
Oropharynx	1	0.1%	1	0
Hypopharynx	2	0.1%	2	0
<b>DIGESTIVE SYSTEM</b>	<b>352</b>	<b>24.4%</b>	<b>176</b>	<b>176</b>
Esophagus	17	1.2%	13	4
Stomach	35	2.4%	20	15
Small Intestine	11	0.8%	6	5
Colon Excluding Rectum	96	6.7%	54	42
Rectum & Rectosigmoid	31	2.1%	8	23
Anus, Anal Canal & Anorectum	9	0.6%	0	9
Liver & Intrahepatic Bile Duct	29	2.0%	14	15
Gallbladder	10	0.7%	2	8
Other Biliary	14	1.0%	8	6
Pancreas	97	6.7%	51	46
Retroperitoneum	1	0.1%	0	1
Peritoneum, Omentum & Mesentery	1	0.1%	0	1
Other Digestive Organs	1	0.1%	0	1
<b>RESPIRATORY SYSTEM</b>	<b>165</b>	<b>11.4%</b>	<b>74</b>	<b>91</b>
Nose, Nasal Cavity & Middle Ear	1	0.1%	1	0
Larynx	6	0.4%	4	2
Lung & Bronchus	157	10.9%	69	88
Trachea, Mediastinum & Other Respiratory Organs	1	0.1%	0	1
<b>SOFT TISSUE INCLUDING HEART</b>	<b>9</b>	<b>0.6%</b>	<b>8</b>	<b>1</b>
<b>SKIN EXCLUDING BASAL &amp; SQUAMOUS</b>	<b>36</b>	<b>2.5%</b>	<b>15</b>	<b>21</b>
Melanoma - Skin	34	2.4%	13	21
Other Non-Epithelial Skin	2	0.1%	2	0
<b>BREAST</b>	<b>366</b>	<b>25.4%</b>	<b>1</b>	<b>365</b>

Body System and Site	Total	%	Male	Female
<b>FEMALE GENITAL SYSTEM</b>	<b>120</b>	<b>8.3%</b>	<b>0</b>	<b>120</b>
Cervix Uteri	5	0.3%	0	5
Corpus & Uterus, NOS	87	6.0%	0	87
Ovary	20	1.4%	0	20
Vulva	3	0.2%	0	3
Other Female Genital Organs	5	0.3%	0	5
<b>MALE GENITAL SYSTEM</b>	<b>171</b>	<b>11.9%</b>	<b>171</b>	<b>0</b>
Prostate	164	11.4%	164	0
Testis	6	0.4%	6	0
Penis	1	0.1%	1	0
<b>URINARY SYSTEM</b>	<b>77</b>	<b>5.3%</b>	<b>56</b>	<b>21</b>
Urinary Bladder	51	3.5%	41	10
Kidney & Renal Pelvis	20	1.4%	13	7
Ureter	6	0.4%	2	4
<b>BRAIN &amp; OTHER NERVOUS SYSTEM</b>	<b>19</b>	<b>1.3%</b>	<b>9</b>	<b>10</b>
Brain	11	0.8%	7	4
Cranial Nerves Other Nervous System	8	0.6%	2	6
<b>ENDOCRINE SYSTEM</b>	<b>21</b>	<b>1.5%</b>	<b>4</b>	<b>17</b>
Thyroid	18	1.2%	3	15
Other Endocrine including Thymus	3	0.2%	1	2
<b>LYMPHOMA</b>	<b>55</b>	<b>3.8%</b>	<b>25</b>	<b>30</b>
Hodgkin Lymphoma	6	0.4%	4	2
Non-Hodgkin Lymphoma	49	3.4%	21	28
<b>MYELOMA</b>	<b>10</b>	<b>0.7%</b>	<b>6</b>	<b>4</b>
<b>LEUKEMIA</b>	<b>7</b>	<b>0.5%</b>	<b>5</b>	<b>2</b>
Lymphocytic Leukemia	1	0.1%	1	0
Myeloid & Monocytic Leukemia	5	0.3%	3	2
Other Leukemia	1	0.1%	1	0
<b>MESOTHELIOMA</b>	<b>5</b>	<b>0.3%</b>	<b>4</b>	<b>1</b>
<b>MISCELLANEOUS</b>	<b>9</b>	<b>0.6%</b>	<b>2</b>	<b>7</b>
<b>Total</b>	<b>1,443</b>		<b>571</b>	<b>872</b>

In a population of 1,443 people treated at NCH for cancer, the male to female ratio was .65. \*Analytic cases: Cases diagnosed at NCH and/or administered any of the first course treatment there.